Skip to main content
MedPathMedPath Home
Clinical Trials/IRCT20191228045924N1
IRCT20191228045924N1
Completed
Phase 3

Evaluation of the efficacy and safety of methylene blue administration for treatment of COVID-19 patients

Mashhad University of Medical Sciences0 sites80 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Mashhad University of Medical Sciences
Enrollment
80
Status
Completed
Last Updated
5 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Confirmed case of Covid\-19 (by RT\-PCR, HRCT)
  • •Admission to intensive care unit
  • •Need for intubation and mechanical ventilation (PaO2/FiO2 \< 100\-200\)
  • •Written informed consent

Exclusion Criteria

  • •Pregnancy and breastfeeding
  • •G6PDH deficiency
  • •Severe renal insufficiency (glomerular filtration rate \<30 mL/min/1\.73m2\)
  • •Active chronic hepatitis
  • •Severe hepatic disease defined by GOT or GPT levels three times above the normal upper limit
  • •Patients with history of allergic reaction or significant sensitivity to methylene blue
  • •Treatment with immunosuppressive agents
  • •Use of other investigational drugs in the moment of inclusion

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 4
A clinical trial to compare the effect of methylphenidate and atomoxetine in children with attention deficit hyperactivity disorder
CTRI/2011/08/001981Department of Psychiatry69
Recruiting
Phase 3
Evaluation of the efficacy and safety of methylprednisolone pulse therapy in treatment of Covid-19 patients with Acute respiratory distress syndrome
IRCT20200406046963N1Artesh University of Medical Sciences40
Completed
Phase 4
A clinical trial to study the effects of two drugs, Metformin Immediate Release and Metformin Extended Release in newly diagnosed type 2 diabetes mellitus patients.Health Condition 1: E119- Type 2 diabetes mellitus without complications
CTRI/2021/04/033194Bangalore Medical College and Research Institute70
Active, not recruiting
Not Applicable
To evaluate the effectiveness of MetaDerm Cream in Atopic Dermatitis
CTRI/2017/06/008950Haus Bioceuticals Inc
Active, not recruiting
Phase 1
Etude d’efficacité et d’acceptabilité du méthylphénidate dans les troubles de la marche de la maladie de Parkinson : Etude multicentrique en double aveugle versus placebo. - PARGKAIT II
EUCTR2008-005801-20-FRCentre Hospitalier Régional et Universitaire de Lille69